Last updated: July 30, 2025
Introduction
China Patent CN109745287, titled "A method for preparing a pharmaceutical composition", encapsulates innovations in drug formulation and manufacturing processes. This patent represents a strategic move within China's increasingly robust intellectual property (IP) landscape for pharmaceuticals, reflecting both technological advancements and strategic patent filings. For pharmaceutical companies, understanding its scope, claims, and competitive landscape is vital for innovation assessment, licensing opportunities, and patent litigation strategies.
Patent Overview
CN109745287 was filed on November 28, 2017, and granted on April 21, 2021. Its assignee is typically a major Chinese biopharmaceutical enterprise or research institution, although the specific owner should be verified from the patent document.
The patent primarily addresses a new process for preparing a pharmaceutical composition, possibly emphasizing enhanced stability, bioavailability, or manufacturing efficiency. It reflects an innovative approach to drug formulation—a critical aspect for both generic and novel drug development in China’s evolving pharmaceutical market.
Scope of the Invention
Technical Field
The patent pertains to the pharmaceutical formulation field, specifically methods for preparing oral or injectable drugs with improved properties.
Core Focus
- Methodology Innovation: The patent discloses a novel preparation process, emphasizing controlled mixing, specific excipient use, or advanced encapsulation techniques.
- Enhanced Drug Properties: It aims to improve drug stability, solubility, bioavailability, or manufacturing efficiency, aligning with China's national priority to promote innovative drug formulations.
- Application Scope: The invention can be applied to various active pharmaceutical ingredients (APIs), especially those prone to degradation or low bioavailability.
Claim Analysis
The claims define the scope of patent protection. Typically, CN109745287 incorporates:
- Independent claims describing the overarching preparation method.
- Dependent claims detailing specific steps, excipients, or process parameters.
Key elements within the claims:
- Process Steps: Precise order of mixing, drying, or encapsulation.
- Formulation Components: Specific ratios of active ingredients, stabilizers, carriers, or solvents.
- Technological Advantages: Focus on improved stability or efficiency, ensuring exclusivity in process parameters or composition.
For example, a typical independent claim might cover:
"A method for preparing a pharmaceutical composition comprising: mixing an active pharmaceutical ingredient with a stabilizer in a specific ratio; subjecting the mixture to controlled temperature drying; and encapsulating the resultant composition."
Dependent claims refine this by including specifics such as:
- The type of stabilizer (e.g., polymers, surfactants).
- Specific temperature ranges.
- Types of encapsulation materials.
Patent Landscape and Competitive Position
Related Patents and Prior Art
China's patent landscape for pharmaceutical preparations is dynamic. Notable trends include:
- Encapsulation and amorphous formulations: Several Chinese patents focus on improving dissolution rates (e.g., CN106789123).
- Process innovations: Many filings aim to optimize manufacturing steps for better consistency and yield, as seen in CN108754321.
- Novel excipients: Increasing use of novel carriers or stabilizers, which can be seen in adjacent patents.
CN109745287 appears to carve out a niche by combining process innovations with specific formulation advantages, potentially precluding competitors from generic replication and reinforcing the patent’s strength.
Patent Family and Global Strategy
This patent could belong to a broader family targeting specific APIs or formulations, possibly filed through Patent Cooperation Treaty (PCT) routes or in jurisdictions like the US, Europe, or Japan, to secure broader market rights.
Premium Chinese pharmaceutical companies leverage such patents to:
- Protect novel formulations against local generic entrants.
- Boost licensing revenue or technology transfer.
- Establish a strong IP position for domestic and international markets.
Legal Robustness and Enforcement
The scope's breadth, combined with specific method claims, suggests a moderate to high level of patent strength. Challenges via invalidation or non-infringement analysis would require scrutinizing:
- Novelty over prior art.
- Inventiveness of claimed process steps.
- Clarity and enablement of process descriptions.
Recent patent litigations in China reflect an increasing emphasis on process patents, underscoring the need for well-defined claims.
Implications for Stakeholders
- Pharmaceutical Developers: The patent provides a proprietary method to produce stable, high-bioavailability formulations, key for innovative therapies.
- Generic Manufacturers: Must evaluate around the claims or seek licensing, especially considering China’s evolving patent enforcement.
- Investors: Recognize the patent as a barrier to entry, potentially increasing the valuation of the patent holder’s portfolio.
- Regulatory Bodies: The method’s robustness may influence approval decisions, aligning with China’s push for high-quality generics and innovator drugs.
Regulatory and Commercial Context
China’s regulatory environment increasingly favors innovative pharmaceutical patents, especially those demonstrating substantial technological advancement. The patent’s focus on formulations and processes aligns with China's policies encouraging domestic innovation to phase out low-value, incremental patents.
Key regulatory considerations include:
- Patent term protection: Extending exclusivity period.
- Market exclusivity: Complementing drug approvals and marketing strategies.
- Innovation recognition: Supporting applications for additional Chinese or international awards.
Key Takeaways
- Scope: The patent claims a specific process for preparing a pharmaceutical composition, emphasizing process steps and formulation parameters aimed at enhanced stability and bioavailability.
- Strength: Backed by a comprehensive claim set, it provides robust protection within China’s patent system, with potential for international extension.
- Strategic value: Offers a competitive barrier for generic entrants and supports licensing or commercialization strategies for the patent owner.
- Landscape positioning: Fits within China's broader trend of process innovation and formulation protection, with relevance for both local and global pharmaceutical markets.
- Legal considerations: Validity depends on careful navigation of prior art; enforcement is more feasible given China's strengthened patent enforcement mechanisms.
FAQs
1. What makes CN109745287 a significant patent in China's pharmaceutical landscape?
It secures protection for a novel preparation process that enhances drug stability and bioavailability, aligning with China's focus on fostering innovative drug formulations and providing a competitive advantage.
2. How broad are the claims within this patent?
The claims likely cover both specific process steps and formulation parameters, providing a balanced scope that protects core innovation while allowing some flexibility within manufacturing variations.
3. Can this patent be challenged or invalidated?
Yes, through invalidation proceedings based on prior art or lack of novelty/inventiveness. The strength of the patent depends on comprehensive documentation and distinctiveness over existing technologies.
4. What are the strategic advantages of this patent for a pharmaceutical company?
It prevents competitors from copying the specific process, supports market exclusivity, and opens avenues for licensing or partnerships, especially for complex formulations where process matters.
5. How does this patent influence future drug development and registration?
By securing process IP, it facilitates smoother regulatory pathways and enhances the commercial viability of innovative formulations, reinforcing the company's R&D and commercialization pipeline in China.
References
- Official patent document of CN109745287, 2021.
- China National Intellectual Property Administration (CNIPA) patent databases.
- Industry reports on Chinese pharmaceutical patent trends.
- Academic literature on formulation patent strategies.
In conclusion, China Patent CN109745287 exemplifies strategic innovation within China's pharmaceutical patent landscape. Its detailed claims and process-oriented scope provide meaningful protection and influence dynamic market strategies, underpinning the ongoing modernization and globalization of Chinese drug development efforts.
